In a letter dated September 18, 2017, Peter G. Traber, MD, President, Chief Executive Officer, Chief Medical Officer and a director of Galectin Therapeutics Inc. informed the board of directors of the company that he does not intend to stand for re-election to the Board at the company’s 2017 Annual Stockholders Meeting, which is scheduled for on or about December 14, 2017. Dr. Traber does not serve on any Board committees. Dr. Traber indicated in the Letter his intention to continue to serve as a director of the company until the expiration of his current term at the 2017 Annual Meeting. Dr. Traber also stated in the Letter that his decision not to stand for re-election to the Board had no relationship to his position as President, CEO and CMO of the company, and he will continue to serve in these capacities in accordance with his contract and at the pleasure of the Board. Dr. Traber’s decision to not stand for re-election was a result of his concerns about the impact of governance constraints placed on the Board by the 10X Fund L.P., the large shareholder of the company and the holder of all the shares of the company’s Series B Convertible Preferred Stock.